- .. taking ustekinumab�a biologic that targets a different aspect of the immune system," gelfand said..
- eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention..
.
.
harvard medical school: "cgrp: a new era for migraine treatment.".